Philadelphia Hematologic Malignancies Conference 2026: Advances in Myeloma, Leukemia, Lymphoma & MDS Care
Accreditation: 6.50 ACPE Pharmacy | 6.50 Nursing Contact Hours | 6.50 ABIM MOC II | 6.50 AMA PRA Category 1 Credit™
Venue: Hilton Philadelphia City Avenue , 4200 City Avenue, Philadelphia, PA, United States
Official conference page for Philadelphia Hematologic Malignancies Conference 2026: Advances in Myeloma, Leukemia, Lymphoma & MDS Care. https://binaytara.org/projects/conferences/philadelphia-hematology-conference
About Philadelphia Hematologic Malignancies Conference 2026: Advances in Myeloma, Leukemia, Lymphoma & MDS Care
Faculty and committee
Conference program and agenda
Our Agenda
Saturday, September 26th, 2026
All timings are in Eastern Time (EDT, GMT-04:00) time.
Session Chair: Alfred Garfall, MD
08:30 AM - 08:35 AM
Speaker Introductions
08:35 AM - 08:45 AM
Topic 1: Smoldering Multiple Myeloma: To Treat or Not to Treat? – Sandra Susanibar-Adaniya, MD, MD
08:45 AM - 08:50 AM
Q&A – Sandra Susanibar-Adaniya, MD, MD
08:50 AM - 09:00 AM
Topic 2: Who Should Receive High-Dose Melphalan and Autologous Stem Cell Transplant in 2026? – Asya Varshavsky, MD
09:00 AM - 09:05 AM
Q&A – Asya Varshavsky, MD
09:05 AM - 09:15 AM
Topic 3: Optimal Therapy for First Relapse: CAR-T Cells or Bispecific Antibodies? – Adam Binder, MD
09:15 AM - 09:20 AM
Q&A – Adam Binder, MD
09:20 AM - 09:50 AM
Case-Based Panel Discussion: Standard-Risk Patient with First Relapse – Mathew Ho
Session Chair: Catherine Lai, MD, MPH
10:35 AM - 10:40 AM
Speaker Introductions
10:40 AM - 10:50 AM
Topic 1: How I Treat Older Patients with Newly Diagnosed AML? – Margaret Kasner, MD
10:50 AM - 10:55 AM
Q&A – Margaret Kasner, MD
10:55 AM - 11:05 AM
Topic 2: The Newest Kid on the Block: Menin Inhibitors – Alexander Perl, MD
11:05 AM - 11:10 AM
Q&A – Alexander Perl, MD
11:10 AM - 11:20 AM
Topic 3: How I treat High-Risk MDS? – Alexander R Vartanov, MD
11:20 AM - 11:25 AM
Q&A – Alexander R Vartanov, MD
11:25 AM - 11:55 AM
Case Based Panel Discussion: TP53 mutated MDS/AML: To Transplant or not to Transplant? – Lukas Ronner, MD
Session Chair: Catherine Lai, MD, MPH
11:55 AM - 12:00 PM
Speaker Introductions
12:00 PM - 12:10 PM
Topic 1: Which JAK Inhibitor do I use as Second Line in MF? – Peter Abdelmessieh, MD
12:10 PM - 12:15 PM
Q&A – Peter Abdelmessieh, MD
12:15 PM - 12:25 PM
Topic 2: How I Treat Transfusion Dependent Low-Intermediate Risk MDS? – Lindsay Wilde, MD
12:25 PM - 12:30 PM
Q&A – Lindsay Wilde, MD
12:30 PM - 12:40 PM
Topic 3: Which TKI should I use for Newly Diagnosed CML? – Ximena Jordan-Bruno , MD
12:40 PM - 12:45 PM
Q&A – Ximena Jordan-Bruno , MD
12:45 PM - 01:15 PM
Case-Based Panel Discussion: Optimal Treatment Sequencing in Low Risk MDS – Wyatt McCall, MD
Session Chair: Marco Ruella, MD
02:15 PM - 02:20 PM
Speaker Introductions
02:20 PM - 02:30 PM
Topic 1: How Frontline Treatment for LBCL is Evolving – Daniel Jeffrey Landsburg, MD
02:30 PM - 02:35 PM
Q&A – Daniel Jeffrey Landsburg, MD
02:35 PM - 02:45 PM
Topic 2: Management of r/r LBCL – Ubaldo E. Martinez Outschoorn, MD
02:45 PM - 02:50 PM
Q&A – Ubaldo E. Martinez Outschoorn, MD
02:50 PM - 03:00 PM
Topic 3: Feasibility of Novel Immunotherapies for NHL in Non-Tertiary Centers
03:00 PM - 03:05 PM
Q&A
03:05 PM - 03:15 PM
Topic 4: The Evolving Landscape of Therapies for T-Cell Lymphomas
03:15 PM - 03:20 PM
Q&A
03:20 PM - 03:50 PM
Case-Based Panel Discussion – Luca Paruzzo
Session Chair: Marco Ruella, MD
03:50 PM - 03:55 PM
Speaker Introductions
03:55 PM - 04:05 PM
Topic 1: Are we Curing Follicular Lymphoma? – Stephen J Schuster
04:05 PM - 04:10 PM
Q&A – Stephen J Schuster
04:10 PM - 04:20 PM
Topic 2: How I treat CLL in 2026 – Shazia Nakhoda, MD
04:20 PM - 04:25 PM
Q&A – Shazia Nakhoda, MD
04:25 PM - 04:35 PM
Topic 3: Latest Updates on the Treatment of Hodgkin Lymphoma – Jakub Svoboda, MD
04:35 PM - 04:40 PM
Q&A – Jakub Svoboda, MD
04:40 PM - 05:10 PM
Case-Based Panel Discussion